Search results for CD99 antibody

APC Anti-CD99 antibody [EPR3096], Abcam, AB306452

This conjugated primary antibody is "made to order" and it is released using a quantitative quality control method that ensures binding affinity and labelling efficiency of the conjugate. Via leveraging the power of the Lightning-Link ® conjugation technology , Abcam will deliver highly consistent recombinant conjugates in <2 weeks, giving you access to an ever growing portfolio of antibody-label combinations. For suitable applications and species reactivity, please refer to the unconjugated version of this clone. How are conjugated primary antibodies validated? This conjugated primary antibody is released using a quantitative quality control method that evaluates binding affinity post-conjugation and efficiency of antibody labeling. For suitable applications and species reactivity, please refer to the unconjugated version of this clone. Patented technology Our RabMAb ® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb ® patents . What are the advantages of a recombinant monoclonal antibody? This product is a recombinant monoclonal antibody, which offers several advantages including: - High batch-to-batch consistency and reproducibility - Improved sensitivity and specificity - Long-term security of supply - Animal-free batch production For more information, read more on recombinant antibodies .

APC Anti-CD99 antibody [EPR3097Y], Abcam, AB305941

This conjugated primary antibody is "made to order" and it is released using a quantitative quality control method that ensures binding affinity and labelling efficiency of the conjugate. Via leveraging the power of the Lightning-Link ® conjugation technology , Abcam will deliver highly consistent recombinant conjugates in <2 weeks, giving you access to an ever growing portfolio of antibody-label combinations. For suitable applications and species reactivity, please refer to the unconjugated version of this clone. How are conjugated primary antibodies validated? This conjugated primary antibody is released using a quantitative quality control method that evaluates binding affinity post-conjugation and efficiency of antibody labeling. For suitable applications and species reactivity, please refer to the unconjugated version of this clone. Patented technology Our RabMAb ® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb ® patents . What are the advantages of a recombinant monoclonal antibody? This product is a recombinant monoclonal antibody, which offers several advantages including: - High batch-to-batch consistency and reproducibility - Improved sensitivity and specificity - Long-term security of supply - Animal-free batch production For more information, read more on recombinant antibodies .

Cluster of Differentiation 99 (CD99) Antibody, Abbexa, abx131325

Cluster Of Differentiation 99 Antibody is a Rabbit Polyclonal against Cluster Of Differentiation 99.

Cluster of Differentiation 99 (CD99) Antibody, Abbexa, abx322868

CD99 Antibody is a Rabbit Polyclonal against CD99.

CD99 antibody [MEM-131] (FITC), Genetex, GTX78313

CD99 antibody [MEM-131] (PE), Genetex, GTX80016

Cluster of Differentiation 99 (CD99) Antibody, Abbexa, abx242868

CD99 Antibody is a Rabbit Polyclonal against CD99.

Cluster of Differentiation 99 (CD99) Antibody, Abbexa, abx270077

Cluster Of Differentiation 99 (CD99) Antibody is a Rabbit Polyclonal Antibody against Cluster Of Differentiation 99 (CD99) for use in flow cytometry.

CD99 antibody (3B2/TA8) [APC], Covalab, Ref 00114857

CD99 antibody (3B2/TA8) [FITC], Covalab, Ref 00114858